%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Anna Turkova, Cecilia L. Moore, Karina Butler, Alexandra Compagnucci, Yacine Saïdi, Victor Musiime, Annet Nanduudu, Elizabeth Kaudha, Tim R. Cressey, Suwalai Chalermpantmetagul, Karen Scott, Lynda Harper, Samuel Montero, Yoann Riault, Torsak Bunupuradah, Alla Volokha, Patricia M. Flynn, Rosa Bologna, Jose T. Ramos Amador, Steven B. Welch, Eleni Nastouli, Nigel Klein, Carlo Giaquinto, Deborah Ford, Abdel Babiker, Diana M. Gibb, on behalf of the BREATHER (PENTA 16) trial Group
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 13 0 R/Annots 14 0 R/Contents 15 0 R/TrimBox[0 0 612 792]>>
endobj
14 0 obj
[16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R]
endobj
16 0 obj
<>/Border[0 0 0]/A 22 0 R>>
endobj
22 0 obj
<>
endobj
17 0 obj
<>/Border[0 0 0]/A 23 0 R>>
endobj
23 0 obj
<>
endobj
18 0 obj
<>/Border[0 0 0]/A 24 0 R>>
endobj
24 0 obj
<>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref001)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref002)>>
endobj
21 0 obj
<>/Border[0 0 0]/A 25 0 R>>
endobj
25 0 obj
<>
endobj
15 0 obj
[26 0 R 27 0 R 28 0 R 29 0 R]
endobj
26 0 obj
<>stream
q
0.45 0.36 0.35 0.01 k
0 w
575.9997 255.5569 m
199.9998 255.5569 l
199.9998 256.0569 l
575.9997 256.0569 l
f*
0.83 0.64 0.02 0 k
239.7543 295.9937 m
308.6362 295.9937 l
h
f*
237.2598 281.9906 m
278.9858 281.9906 l
h
f*
272.9197 267.9874 m
334.0913 267.9874 l
h
f*
353.4236 172.9134 m
358.1858 172.9134 l
h
f*
224.7874 133.9087 m
229.5496 133.9087 l
h
f*
0 g
1 j
1 J
9.5 0 0 9.5 200.0125 707.7543 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(and)Tj
1.8619 0 Td
(African/non-Afr)Tj
6.6062 0 Td
(ican)Tj
2.023 0 Td
(sites,)Tj
2.5303 0 Td
(to)Tj
1.0443 0 Td
(remain)Tj
3.2405 0 Td
(on)Tj
1.3128 0 Td
(CT)Tj
1.5457 0 Td
(or)Tj
1.098 0 Td
(change)Tj
3.4553 0 Td
(to)Tj
1.0443 0 Td
(SCT.)Tj
2.4885 0 Td
(The)Tj
1.9276 0 Td
(Kaplan-Meier)Tj
6.093 0 Td
(method)Tj
-36.2714 -1.474 Td
(was)Tj
1.9812 0 Td
(used)Tj
2.3632 0 Td
(to)Tj
1.0443 0 Td
(estimate)Tj
3.9626 0 Td
(the)Tj
1.5933 0 Td
(proportion)Tj
4.6667 0 Td
(of)Tj
1.0444 0 Td
(participants)Tj
5.2694 0 Td
(with)Tj
1.9813 0 Td
(viral)Tj
2.023 0 Td
(rebound)Tj
3.8432 0 Td
(\(confirmed)Tj
4.8935 0 Td
(VL)Tj
/F12 1 Tf
0 Tc
()Tj
/F0 1 Tf
-0.0042 Tc
(50)Tj
-34.6661 -1.474 Td
(copies/mL\))Tj
5.0605 0 Td
(under)Tj
2.7451 0 Td
(intent-to-treat)Tj
6.099 0 Td
(at)Tj
1.0503 0 Td
(48)Tj
1.3129 0 Td
(weeks)Tj
3.0315 0 Td
(\(primary)Tj
3.8432 0 Td
(outcome\),)Tj
4.6309 0 Td
(and)Tj
1.8619 0 Td
(in)Tj
0.9847 0 Td
(extended)Tj
4.2848 0 Td
(follow-up)Tj
-34.9048 -1.474 Td
(at)Tj
1.0443 0 Td
(96,)Tj
1.5934 0 Td
(144,)Tj
2.1483 0 Td
(and)Tj
1.8619 0 Td
(192)Tj
1.8679 0 Td
(weeks.)Tj
3.3061 0 Td
(SCT)Tj
2.208 0 Td
(participants)Tj
5.2694 0 Td
(returned)Tj
3.9029 0 Td
(to)Tj
1.0443 0 Td
(CT)Tj
1.5457 0 Td
(following)Tj
4.052 0 Td
(viral)Tj
2.029 0 Td
(rebound,)Tj
4.1177 0 Td
(3)Tj
0.7698 0 Td
(VL)Tj
-36.7607 -1.474 Td
(blips)Tj
2.2438 0 Td
(or)Tj
1.098 0 Td
(discontinuation)Tj
6.8032 0 Td
(of)Tj
1.0443 0 Td
(efavirenz.)Tj
ET
Q
q
1 j
1 J
0 w
11.4998 0 0 11.4998 200.0125 625.1527 cm
BT
/F2 1 Tf
1 TL
-0.0035 Tc
0 0 Td
(Findings)Tj
ET
Q
q
1 j
1 J
0 w
9.5 0 0 9.5 200.0125 608.1448 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(Of)Tj
1.277 0 Td
(199)Tj
1.8619 0 Td
(participants)Tj
5.2754 0 Td
(\(99)Tj
1.6471 0 Td
(SCT,)Tj
2.4826 0 Td
(100)Tj
1.8678 0 Td
(CT\),)Tj
2.1544 0 Td
(97)Tj
1.3188 0 Td
(per)Tj
1.6471 0 Td
(arm)Tj
1.9275 0 Td
(consented)Tj
4.7861 0 Td
(to)Tj
1.0443 0 Td
(extended)Tj
4.2848 0 Td
(follow-up.)Tj
4.4459 0 Td
(Median)Tj
-36.0207 -1.468 Td
(follow-up)Tj
4.1654 0 Td
(was)Tj
1.9812 0 Td
(185.3)Tj
2.6914 0 Td
(weeks)Tj
3.0256 0 Td
(\(IQR)Tj
2.3215 0 Td
(160.9216.1\).)Tj
6.3197 0 Td
(69)Tj
1.3189 0 Td
(\(70%\))Tj
2.8585 0 Td
(SCT)Tj
2.214 0 Td
(participants)Tj
5.2694 0 Td
(remained)Tj
4.3385 0 Td
(on)Tj
-36.5041 -1.474 Td
(SCT)Tj
2.208 0 Td
(at)Tj
1.0443 0 Td
(last)Tj
1.7605 0 Td
(follow-up.)Tj
4.4459 0 Td
(105)Tj
1.8679 0 Td
(\(53%\))Tj
2.8585 0 Td
(were)Tj
2.3632 0 Td
(male,)Tj
2.6377 0 Td
(baseline)Tj
3.8909 0 Td
(median)Tj
3.4612 0 Td
(age)Tj
1.8619 0 Td
(14)Tj
1.3189 0 Td
(years)Tj
2.6436 0 Td
(\(IQR)Tj
2.3155 0 Td
(1218\),)Tj
-34.678 -1.474 Td
(median)Tj
3.4612 0 Td
(CD4)Tj
2.1961 0 Td
(count)Tj
2.6437 0 Td
(735)Tj
1.8619 0 Td
(cells/)Tj
/F8 1 Tf
[()]TJ
/F0 1 Tf
(L)Tj
3.5925 0 Td
(\(IQR)Tj
2.3154 0 Td
(576968\).)Tj
4.6727 0 Td
(16)Tj
1.3129 0 Td
(SCT)Tj
2.214 0 Td
(and)Tj
1.8679 0 Td
(16)Tj
1.3129 0 Td
(CT)Tj
1.5516 0 Td
(participants)Tj
5.2694 0 Td
(had)Tj
1.8679 0 Td
(con-)Tj
-36.1401 -1.474 Td
(firmed)Tj
2.9659 0 Td
(VL)Tj
/F12 1 Tf
0 Tc
()Tj
/F0 1 Tf
-0.0042 Tc
(50)Tj
3.3061 0 Td
(copies/mL)Tj
4.7263 0 Td
(by)Tj
1.2652 0 Td
(the)Tj
1.5993 0 Td
(end)Tj
1.8619 0 Td
(of)Tj
1.0503 0 Td
(extended)Tj
4.2848 0 Td
(follow-up)Tj
4.1654 0 Td
(\(HR)Tj
1.9813 0 Td
(1.00,)Tj
2.4229 0 Td
(95%)Tj
2.202 0 Td
(CI)Tj
1.2115 0 Td
(0.502.00\).)Tj
-33.0429 -1.474 Td
(Estimated)Tj
4.6249 0 Td
(difference)Tj
4.5593 0 Td
(in)Tj
0.9846 0 Td
(percentage)Tj
5.1621 0 Td
(with)Tj
1.9812 0 Td
(viral)Tj
2.0231 0 Td
(rebound)Tj
3.8431 0 Td
(\(SCT)Tj
2.5363 0 Td
(minus)Tj
2.8585 0 Td
(CT\))Tj
1.8798 0 Td
(by)Tj
1.2651 0 Td
(week)Tj
2.5303 0 Td
(144)Tj
1.8679 0 Td
(was)Tj
-36.1162 -1.474 Td
(1.9%)Tj
2.4765 0 Td
(\(90%)Tj
2.5303 0 Td
(CI)Tj
1.2114 0 Td
(-6.610.4;)Tj
4.6727 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7997 0 Td
(0.72\))Tj
2.4766 0 Td
(and)Tj
1.8619 0 Td
(was)Tj
1.9813 0 Td
(similar)Tj
3.0733 0 Td
(in)Tj
0.9847 0 Td
(a)Tj
0.7638 0 Td
(per-protoc)Tj
4.5116 0 Td
(ol)Tj
0.9787 0 Td
(analysis.)Tj
4.0639 0 Td
(There)Tj
2.8108 0 Td
(were)Tj
2.3632 0 Td
(no)Tj
-38.3302 -1.4741 Td
(significant)Tj
4.607 0 Td
(differences)Tj
5.0546 0 Td
(between)Tj
3.9565 0 Td
(arms)Tj
2.4289 0 Td
(in)Tj
0.9787 0 Td
(proportions)Tj
5.162 0 Td
(of)Tj
1.0443 0 Td
(participants)Tj
5.2754 0 Td
(with)Tj
1.9753 0 Td
(grade)Tj
2.7452 0 Td
(3/4)Tj
1.5933 0 Td
(adverse)Tj
-34.8212 -1.474 Td
(events)Tj
3.133 0 Td
(\(18)Tj
1.647 0 Td
(SCT)Tj
2.214 0 Td
(vs)Tj
1.2115 0 Td
(16)Tj
1.3188 0 Td
(CT)Tj
1.5457 0 Td
(participants;)Tj
5.5499 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7997 0 Td
(0.71\))Tj
2.4706 0 Td
(or)Tj
1.098 0 Td
(ART-related)Tj
5.5559 0 Td
(adverse)Tj
3.7417 0 Td
(events)Tj
3.133 0 Td
(\(10)Tj
1.6471 0 Td
(vs)Tj
1.2174 0 Td
(12;)Tj
-37.0531 -1.474 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7996 0 Td
(0.82\).)Tj
2.7511 0 Td
(20)Tj
1.3129 0 Td
(versus)Tj
3.139 0 Td
(8)Tj
0.7698 0 Td
(serious)Tj
3.4016 0 Td
(adverse)Tj
3.7357 0 Td
(events)Tj
3.139 0 Td
(\(SAEs\))Tj
3.3658 0 Td
(were)Tj
2.3632 0 Td
(reported)Tj
3.9028 0 Td
(in)Tj
0.9847 0 Td
(16)Tj
1.3129 0 Td
(SCT)Tj
2.214 0 Td
(versus)Tj
3.133 0 Td
(4)Tj
0.7698 0 Td
(CT)Tj
-37.8647 -1.474 Td
(participants,)Tj
5.5499 0 Td
(respectively)Tj
5.4365 0 Td
(\(p)Tj
1.0981 0 Td
(=)Tj
0.7996 0 Td
(0.005)Tj
2.6914 0 Td
(comparing)Tj
4.8338 0 Td
(proportions)Tj
5.1621 0 Td
(between)Tj
3.9565 0 Td
(groups;)Tj
3.5209 0 Td
(incidence)Tj
4.3863 0 Td
(rate)Tj
-37.4351 -1.474 Td
(ratio)Tj
2.1364 0 Td
(2.49,)Tj
2.4228 0 Td
(95%CI)Tj
3.1927 0 Td
(0.718.66,)Tj
4.8935 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7997 0 Td
(0.15\).)Tj
2.7511 0 Td
(75%)Tj
2.2021 0 Td
(of)Tj
1.0443 0 Td
(SAEs)Tj
2.7033 0 Td
(\(15)Tj
1.6471 0 Td
(SCT,)Tj
2.4885 0 Td
(6)Tj
0.7699 0 Td
(CT\))Tj
1.8798 0 Td
(were)Tj
2.3632 0 Td
(hospitalisations)Tj
-32.0642 -1.474 Td
(for)Tj
1.3725 0 Td
(a)Tj
0.7698 0 Td
(wide)Tj
2.2498 0 Td
(range)Tj
2.7452 0 Td
(of)Tj
1.0443 0 Td
(conditions.)Tj
4.9412 0 Td
(3)Tj
0.7699 0 Td
(SCT)Tj
2.208 0 Td
(and)Tj
1.8679 0 Td
(6)Tj
0.7698 0 Td
(CT)Tj
1.5456 0 Td
(participants)Tj
5.2695 0 Td
(switched)Tj
4.0699 0 Td
(to)Tj
1.0443 0 Td
(second-line)Tj
5.2635 0 Td
(ART)Tj
2.214 0 Td
(fol-)Tj
-38.1452 -1.474 Td
(lowing)Tj
3.0076 0 Td
(viral)Tj
2.0291 0 Td
(failure)Tj
2.9002 0 Td
(\(p)Tj
1.0981 0 Td
(=)Tj
0.7996 0 Td
(0.50\).)Tj
ET
Q
q
1 j
1 J
0 w
11.4998 0 0 11.4998 200.0125 399.6283 cm
BT
/F2 1 Tf
1 TL
-0.0035 Tc
0 0 Td
(Conclusions)Tj
ET
Q
q
1 j
1 J
0 w
9.5 0 0 9.5 200.0125 382.6204 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(Sustainable)Tj
5.3768 0 Td
(non-inferiority)Tj
6.2004 0 Td
(of)Tj
1.0443 0 Td
(virological)Tj
4.5951 0 Td
(suppression)Tj
5.55 0 Td
(in)Tj
0.9846 0 Td
(young)Tj
2.9122 0 Td
(people)Tj
3.1748 0 Td
(was)Tj
1.9813 0 Td
(shown)Tj
3.0793 0 Td
(for)Tj
1.3726 0 Td
(SCT)Tj
-36.2714 -1.474 Td
(versus)Tj
3.133 0 Td
(CT)Tj
1.5516 0 Td
(over)Tj
2.1423 0 Td
(median)Tj
3.4613 0 Td
(3.6)Tj
1.5934 0 Td
(years.)Tj
2.9181 0 Td
(Standard-dose)Tj
6.7077 0 Td
(efavirenz-based)Tj
7.2507 0 Td
(SCT)Tj
2.208 0 Td
(is)Tj
0.931 0 Td
(a)Tj
0.7698 0 Td
(viable)Tj
2.7929 0 Td
(option)Tj
2.9062 0 Td
(for)Tj
-38.366 -1.474 Td
(virologically)Tj
5.3052 0 Td
(suppressed)Tj
5.3351 0 Td
(HIV-1)Tj
2.7511 0 Td
(infected)Tj
3.682 0 Td
(young)Tj
2.9122 0 Td
(people)Tj
3.1808 0 Td
(on)Tj
1.3188 0 Td
(first-line)Tj
3.6701 0 Td
(ART)Tj
2.2081 0 Td
(with)Tj
1.9812 0 Td
(3-monthly)Tj
4.5593 0 Td
(VL)Tj
-36.9039 -1.474 Td
(monitoring.)Tj
ET
Q
q
1 j
1 J
0 w
11.4998 0 0 11.4998 200.0125 314.0787 cm
BT
/F2 1 Tf
1 TL
-0.0035 Tc
0 0 Td
(Trial)Tj
2.317 0 Td
(registration)Tj
ET
Q
q
1 j
1 J
0 w
9.5 0 0 9.5 200.0125 297.0708 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(EudraCT)Tj
0.83 0.64 0.02 0 k
4.1833 0 Td
(2009-012947-40)Tj
0 g
-4.1833 -1.474 Td
(ISRCTN)Tj
0.83 0.64 0.02 0 k
3.9207 0 Td
(97755073)Tj
0 g
-3.9207 -1.474 Td
(ClinicalTrials.gov)Tj
0.83 0.64 0.02 0 k
7.6744 0 Td
(NCT01641016)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 203.9811 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 186.9732 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(An)Tj
1.4513 0 Td
(estimated)Tj
4.0705 0 Td
(37)Tj
1.1735 0 Td
(million)Tj
3.1238 0 Td
(adults)Tj
2.6135 0 Td
(and)Tj
1.7292 0 Td
(children,)Tj
3.7813 0 Td
(including)Tj
4.0422 0 Td
(4)Tj
0.6973 0 Td
(million)Tj
3.1181 0 Td
(young)Tj
2.7269 0 Td
(people)Tj
2.8517 0 Td
(\(aged)Tj
2.4151 0 Td
(1524)Tj
-33.7944 -1.2982 Td
(years\))Tj
2.6021 0 Td
(are)Tj
1.4514 0 Td
(living)Tj
2.4661 0 Td
(with)Tj
2.0012 0 Td
(HIV)Tj
2.0183 0 Td
(worldwide)Tj
4.4617 0 Td
([)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(].)Tj
1.5987 0 Td
(With)Tj
2.2791 0 Td
(scale)Tj
2.1089 0 Td
(up)Tj
1.2643 0 Td
(of)Tj
1.0148 0 Td
(antiretroviral)Tj
5.5162 0 Td
(therapy)Tj
3.2428 0 Td
(\(ART\))Tj
2.8176 0 Td
(a)Tj
-34.8432 -1.2983 Td
(growing)Tj
3.5262 0 Td
(proportion)Tj
4.6318 0 Td
(of)Tj
1.0148 0 Td
(perinatally-infected)Tj
8.0107 0 Td
(children)Tj
3.5603 0 Td
(are)Tj
1.4456 0 Td
(surviving)Tj
3.9401 0 Td
(into)Tj
1.8369 0 Td
(adolescence)Tj
4.9663 0 Td
(and)Tj
-32.9327 -1.2982 Td
(beyond,)Tj
3.4128 0 Td
(contributing)Tj
5.2498 0 Td
(to)Tj
1.0261 0 Td
(increasing)Tj
4.3313 0 Td
(numbers)Tj
3.7757 0 Td
(of)Tj
1.0148 0 Td
(youth)Tj
2.5342 0 Td
(living)Tj
2.4718 0 Td
(with)Tj
1.9956 0 Td
(HIV)Tj
2.0239 0 Td
(and)Tj
1.7291 0 Td
(requiring)Tj
3.9685 0 Td
(life-long)Tj
-33.5336 -1.304 Td
(ART)Tj
2.1373 0 Td
([)Tj
0.83 0.64 0.02 0 k
(2)Tj
0 g
(].)Tj
1.5987 0 Td
(In)Tj
1.1112 0 Td
(the)Tj
1.4683 0 Td
(current)Tj
3.1861 0 Td
(era)Tj
1.4457 0 Td
(of)Tj
1.0148 0 Td
(universal)Tj
3.8551 0 Td
(life-long)Tj
3.5603 0 Td
(ART)Tj
2.1373 0 Td
(for)Tj
1.3889 0 Td
(all)Tj
1.1452 0 Td
(people)Tj
2.8573 0 Td
(living)Tj
2.4662 0 Td
(with)Tj
1.9955 0 Td
(HIV,)Tj
2.2507 0 Td
(there)Tj
2.2621 0 Td
(is)Tj
-35.8807 -1.2982 Td
(an)Tj
1.2018 0 Td
(increased)Tj
3.9969 0 Td
(interest)Tj
3.2144 0 Td
(in)Tj
1.0375 0 Td
(ART)Tj
2.1373 0 Td
(reduction)Tj
4.1102 0 Td
(strategies)Tj
3.9231 0 Td
(that)Tj
1.7802 0 Td
(could)Tj
2.4548 0 Td
(offer)Tj
2.0976 0 Td
(lower)Tj
2.4491 0 Td
(cumulative)Tj
4.6431 0 Td
(long-term)Tj
-33.046 -1.2983 Td
(toxicity,)Tj
3.4242 0 Td
(better)Tj
2.5455 0 Td
(engagement)Tj
5.0683 0 Td
(with)Tj
1.9956 0 Td
(treatment)Tj
4.1385 0 Td
(and)Tj
1.7291 0 Td
(substantial)Tj
4.5014 0 Td
(costs-savings.)Tj
-22.2064 -1.3039 Td
(Young)Tj
2.9026 0 Td
(people)Tj
2.8573 0 Td
(face)Tj
1.7858 0 Td
(major)Tj
2.6079 0 Td
(challenges)Tj
4.32 0 Td
(growing)Tj
3.5319 0 Td
(up)Tj
1.2643 0 Td
(with)Tj
1.9955 0 Td
(HIV.)Tj
2.2451 0 Td
(Adolescents)Tj
5.0286 0 Td
(and)Tj
1.7291 0 Td
(young)Tj
2.7213 0 Td
(adults)Tj
-34.1856 -1.2983 Td
(have)Tj
2.0579 0 Td
(poorer)Tj
2.914 0 Td
(adherence,)Tj
4.5467 0 Td
(lower)Tj
2.4548 0 Td
(rates)Tj
2.1033 0 Td
(of)Tj
1.0148 0 Td
(virological)Tj
4.4107 0 Td
(suppression,)Tj
5.2044 0 Td
(higher)Tj
2.8006 0 Td
(rates)Tj
2.1089 0 Td
(of)Tj
1.0148 0 Td
(virological)Tj
4.405 0 Td
(failure)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 257.6692 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Weekends-)Tj
4.9819 0 Td
(off)Tj
1.3181 0 Td
(efaviren)Tj
3.4866 0 Td
(z-based)Tj
3.7205 0 Td
(antiretrov)Tj
4.0891 0 Td
(iral)Tj
1.5236 0 Td
(therapy:)Tj
3.7701 0 Td
(BREATHER)Tj
5.5985 0 Td
(extended)Tj
4.2661 0 Td
(follow-up)Tj
4.1387 0 Td
(results)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01962)Tj
4.089 0 Td
(39)Tj
0 g
2.0906 0 Td
(April)Tj
2.1827 0 Td
(23,)Tj
1.5874 0 Td
(2018)Tj
35.1357 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(17)Tj
/F10 1 Tf
-0.025 Tc
-66.402 84.0904 Td
(funded)Tj
2.7921 0 Td
(clinical)Tj
2.7284 0 Td
(trials)Tj
2.0126 0 Td
(be)Tj
1.1126 0 Td
(shared?)Tj
3.2102 0 Td
(BMC)Tj
2.0268 0 Td
(Med.)Tj
-13.8827 -1.3748 Td
(2015;13:298.)Tj
/F9 1 Tf
0 -2.126 Td
(Funding:)Tj
/F10 1 Tf
3.5716 0 Td
(The)Tj
1.5874 0 Td
(study)Tj
2.2678 0 Td
(was)Tj
1.7008 0 Td
(funded)Tj
2.7921 0 Td
(by)Tj
1.1126 0 Td
(UK)Tj
1.3323 0 Td
(Medical)Tj
-14.3646 -1.3749 Td
(Research)Tj
3.6992 0 Td
(Council,)Tj
3.1961 0 Td
(UK)Tj
1.3323 0 Td
(National)Tj
3.2386 0 Td
(Institute)Tj
3.2244 0 Td
(for)Tj
1.2544 0 Td
(Health)Tj
-15.945 -1.3748 Td
(Research)Tj
3.6992 0 Td
(Health)Tj
2.5654 0 Td
(Technology)Tj
4.5213 0 Td
(Assessme)Tj
3.8055 0 Td
(nt)Tj
0.9496 0 Td
(\(08/53/)Tj
-15.541 -1.3748 Td
(25;11/13)Tj
3.3165 0 Td
(6/108\),)Tj
2.9055 0 Td
(European)Tj
3.7347 0 Td
(Commission)Tj
-9.9567 -1.3748 Td
(\(EuroCoor)Tj
3.8126 0 Td
(d)Tj
0.6945 0 Td
(FP7/2007/20)Tj
4.7693 0 Td
(15\),)Tj
1.7008 0 Td
(the)Tj
1.3677 0 Td
(Paediatric)Tj
-12.3449 -1.3748 Td
(European)Tj
3.7346 0 Td
(Network)Tj
3.3308 0 Td
(for)Tj
1.2543 0 Td
(Treatment)Tj
4.004 0 Td
(of)Tj
0.9496 0 Td
(AIDS)Tj
2.1118 0 Td
(\(PENTA\))Tj
-15.3851 -1.3748 Td
(Foundation)Tj
4.3512 0 Td
(and)Tj
1.5874 0 Td
(the)Tj
1.3748 0 Td
(French)Tj
2.7354 0 Td
(National)Tj
3.2387 0 Td
(Institute)Tj
3.2244 0 Td
(of)Tj
-16.5119 -1.3748 Td
(Health)Tj
2.5724 0 Td
(and)Tj
1.5874 0 Td
(Medical)Tj
3.0969 0 Td
(Research)Tj
3.6992 0 Td
(and)Tj
1.5875 0 Td
(French)Tj
2.7354 0 Td
(AIDS)Tj
-15.2788 -1.3749 Td
(Research)Tj
3.6992 0 Td
(Agency)Tj
2.9551 0 Td
(\(INSERM)Tj
3.4867 0 Td
(-ANRS\).)Tj
3.2882 0 Td
(The)Tj
1.5874 0 Td
(qualitative)Tj
-15.0166 -1.3748 Td
(substudy)Tj
3.6354 0 Td
(was)Tj
1.7008 0 Td
(additionally)Tj
4.4079 0 Td
(funded)Tj
2.7851 0 Td
(by)Tj
1.1197 0 Td
(the)Tj
1.3677 0 Td
(Economic)Tj
-15.0166 -1.3748 Td
(and)Tj
1.5874 0 Td
(Social)Tj
2.452 0 Td
(Researc)Tj
2.9976 0 Td
(h)Tj
0.6945 0 Td
(Council)Tj
2.9764 0 Td
(\(RES-062-)Tj
3.926 0 Td
(23-2308\))Tj
3.4512 0 Td
(.)Tj
-18.0851 -1.3748 Td
(The)Tj
1.5874 0 Td
(trial)Tj
1.5945 0 Td
(was)Tj
1.7008 0 Td
(sponsored)Tj
4.1598 0 Td
(by)Tj
1.1126 0 Td
(PENTA)Tj
2.8064 0 Td
(Foundation.)Tj
-12.9615 -1.3748 Td
(This)Tj
1.7787 0 Td
(work)Tj
2.0622 0 Td
(was)Tj
1.7079 0 Td
(supporte)Tj
3.2953 0 Td
(d)Tj
0.6945 0 Td
(by)Tj
1.1126 0 Td
(core)Tj
1.8425 0 Td
(funding)Tj
3.0402 0 Td
(to)Tj
0.9496 0 Td
(the)Tj
1.3678 0 Td
(UK)Tj
-17.8513 -1.3748 Td
(Medical)Tj
3.0968 0 Td
(Research)Tj
3.6993 0 Td
(Council)Tj
2.9693 0 Td
([MC_UU_)Tj
3.7063 0 Td
(12023/26].)Tj
-13.4717 -1.3748 Td
(The)Tj
1.5874 0 Td
(funders)Tj
3.0472 0 Td
(had)Tj
1.5874 0 Td
(no)Tj
1.1693 0 Td
(direct)Tj
2.289 0 Td
(role)Tj
1.6158 0 Td
(in)Tj
0.8858 0 Td
(study)Tj
2.2678 0 Td
(design,)Tj
2.8984 0 Td
(data)Tj
-17.3481 -1.3748 Td
(collection,)Tj
3.9614 0 Td
(analysis,)Tj
3.4158 0 Td
(interpret)Tj
3.1039 0 Td
(ation,)Tj
2.2607 0 Td
(report)Tj
2.4591 0 Td
(writing,)Tj
2.9764 0 Td
(or)Tj
-18.1773 -1.3749 Td
(the)Tj
1.3677 0 Td
(decision)Tj
3.2953 0 Td
(to)Tj
0.9496 0 Td
(submit)Tj
2.7851 0 Td
(for)Tj
1.2614 0 Td
(publica)Tj
2.6433 0 Td
(tion.)Tj
/F9 1 Tf
-12.3024 -2.126 Td
(Competing)Tj
4.3795 0 Td
(interests)Tj
3.3307 0 Td
(:)Tj
/F10 1 Tf
0.4819 0 Td
(The)Tj
1.5875 0 Td
(authors)Tj
3.0401 0 Td
(have)Tj
1.963 0 Td
(declared)Tj
-14.7827 -1.3748 Td
(that)Tj
1.6228 0 Td
(no)Tj
1.1693 0 Td
(competing)Tj
4.1599 0 Td
(interests)Tj
ET
endstream
endobj
27 0 obj
<>stream
endstream
endobj
28 0 obj
<>stream
endstream
endobj
29 0 obj
<>stream
BT
10.3394 55.0917 Td
(exist.)Tj
ET
Q
endstream
endobj
30 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 13 0 R/Annots 34 0 R/Contents 35 0 R/TrimBox[0 0 612 792]>>
endobj
34 0 obj
[36 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 42 0 R 43 0 R 44 0 R 45 0 R 46 0 R 47 0 R 48 0 R 49 0 R 50 0 R 51 0 R 52 0 R 53 0 R 54 0 R 55 0 R 56 0 R]
endobj
36 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref003)>>
endobj
37 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref004)>>
endobj
38 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref005)>>
endobj
39 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref006)>>
endobj
40 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref005)>>
endobj
41 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref007)>>
endobj
42 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref008)>>
endobj
43 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref007)>>
endobj
44 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref009)>>
endobj
45 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref010)>>
endobj
46 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref011)>>
endobj
47 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref006)>>
endobj
48 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref007)>>
endobj
49 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref012)>>
endobj
50 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref013)>>
endobj
51 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref014)>>
endobj
52 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref015)>>
endobj
53 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref016)>>
endobj
54 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref017)>>
endobj
55 0 obj
<>/Border[0 0 0]/Dest(Rpone.0196239.ref015)>>
endobj
56 0 obj
<>/Border[0 0 0]/A 57 0 R>>
endobj
57 0 obj
<>
endobj
35 0 obj
[58 0 R 59 0 R 60 0 R 61 0 R 62 0 R 63 0 R 64 0 R 65 0 R 66 0 R 67 0 R 68 0 R 69 0 R 70 0 R 71 0 R 72 0 R 73 0 R 74 0 R 75 0 R]
endobj
58 0 obj
<>stream
q
0.83 0.64 0.02 0 k
203.4142 706.337 m
208.1764 706.337 l
h
f*
212.5984 706.337 m
217.3606 706.337 l
h
f*
291.7417 706.337 m
296.5039 706.337 l
h
f*
300.9827 706.337 m
305.6882 706.337 l
h
f*
510.9732 706.337 m
515.7354 706.337 l
h
f*
520.1575 706.337 m
524.9197 706.337 l
h
f*
259.4268 680.315 m
264.189 680.315 l
h
f*
203.4142 654.3496 m
208.1764 654.3496 l
h
f*
212.5984 654.3496 m
217.3606 654.3496 l
h
f*
221.8394 654.3496 m
231.3071 654.3496 l
h
f*
309.4299 628.3276 m
318.9543 628.3276 l
h
f*
203.4142 589.3228 m
208.1764 589.3228 l
h
f*
212.5984 589.3228 m
217.3606 589.3228 l
h
f*
356.485 485.348 m
366.0094 485.348 l
h
f*
481.8331 472.3087 m
491.3575 472.3087 l
h
f*
317.0835 420.3213 m
326.6079 420.3213 l
h
f*
523.1622 303.3071 m
532.5165 303.3071 l
h
f*
462.4441 264.3024 m
471.8551 264.3024 l
h
f*
203.3575 238.337 m
212.7118 238.337 l
h
f*
308.6362 120.926 m
318.1606 120.926 l
h
f*
0 g
1 j
1 J
0 w
10 0 0 10 200.0125 707.4141 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
([)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.2585 0 Td
(4)Tj
0 g
(],)Tj
1.2643 0 Td
(higher)Tj
2.8006 0 Td
(attrition)Tj
3.5093 0 Td
([)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.2642 0 Td
(6)Tj
0 g
(])Tj
1.0318 0 Td
(and)Tj
1.7291 0 Td
(ultimately)Tj
4.2406 0 Td
(higher)Tj
2.8006 0 Td
(mortality)Tj
3.9175 0 Td
(than)Tj
2.0296 0 Td
(older)Tj
2.296 0 Td
(adults)Tj
2.6136 0 Td
([)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.2585 0 Td
(7)Tj
0 g
(].)Tj
1.2643 0 Td
(HIV)Tj
2.0182 0 Td
(is)Tj
-35.2967 -1.3039 Td
(now)Tj
1.9558 0 Td
(the)Tj
1.474 0 Td
(second)Tj
3.0104 0 Td
(leading)Tj
3.1295 0 Td
(cause)Tj
2.3924 0 Td
(of)Tj
1.0148 0 Td
(death)Tj
2.4321 0 Td
(and)Tj
1.7291 0 Td
(the)Tj
1.4683 0 Td
(fourth)Tj
2.7383 0 Td
(leading)Tj
3.1351 0 Td
(cause)Tj
2.3868 0 Td
(of)Tj
1.0147 0 Td
(disability)Tj
3.8551 0 Td
(among)Tj
2.9934 0 Td
(adoles-)Tj
-34.7298 -1.2982 Td
(cents)Tj
2.2733 0 Td
(globally)Tj
3.3279 0 Td
([)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(].)Tj
1.5987 0 Td
(Social)Tj
2.5738 0 Td
(marginalisation,)Tj
6.7124 0 Td
(treatment)Tj
4.1386 0 Td
(fatigue,)Tj
3.1464 0 Td
(stigma)Tj
2.8687 0 Td
(and)Tj
1.7291 0 Td
(the)Tj
1.4683 0 Td
(burden)Tj
3.1295 0 Td
(of)Tj
1.0148 0 Td
(secrecy)Tj
-33.9815 -1.2983 Td
(around)Tj
3.135 0 Td
(the)Tj
1.4684 0 Td
(diagnosis)Tj
3.9571 0 Td
(are)Tj
1.4514 0 Td
(recognised)Tj
4.5354 0 Td
(to)Tj
1.0261 0 Td
(be)Tj
1.1509 0 Td
(critical)Tj
2.9536 0 Td
(factors)Tj
2.9027 0 Td
(associated)Tj
4.2576 0 Td
(with)Tj
1.9956 0 Td
(poor)Tj
2.1203 0 Td
(health)Tj
2.6815 0 Td
(outcomes)Tj
-33.6356 -1.2983 Td
([)Tj
0.83 0.64 0.02 0 k
(7)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.2585 0 Td
(9)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
0.9241 0 Td
(10)Tj
0 g
(].)Tj
-0.9864 -1.3039 Td
(There)Tj
2.5795 0 Td
(is)Tj
0.8504 0 Td
(an)Tj
1.2018 0 Td
(urgent)Tj
2.8517 0 Td
(need)Tj
2.143 0 Td
(for)Tj
1.3889 0 Td
(effective)Tj
3.5093 0 Td
(interventions)Tj
5.5389 0 Td
(to)Tj
1.0261 0 Td
(help)Tj
1.9332 0 Td
(young)Tj
2.7213 0 Td
(people)Tj
2.8573 0 Td
(stay)Tj
1.7688 0 Td
(on)Tj
1.2755 0 Td
(treatment)Tj
-32.8419 -1.2982 Td
(and)Tj
1.7291 0 Td
(engaged)Tj
3.5092 0 Td
(in)Tj
1.0318 0 Td
(healthcare)Tj
4.3314 0 Td
([)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(].)Tj
2.0749 0 Td
(A)Tj
0.9071 0 Td
(number)Tj
3.4185 0 Td
(of)Tj
1.0148 0 Td
(youth-focused)Tj
5.9414 0 Td
(interventions,)Tj
5.7657 0 Td
(including)Tj
4.0421 0 Td
(youth-)Tj
-33.766 -1.2983 Td
(friendly)Tj
3.3448 0 Td
(health)Tj
2.6759 0 Td
(services,)Tj
3.5319 0 Td
(psychosocial)Tj
5.2498 0 Td
(interventions)Tj
5.5388 0 Td
(and)Tj
1.7292 0 Td
(peer)Tj
1.9559 0 Td
(support)Tj
3.3221 0 Td
(groups,)Tj
3.1918 0 Td
(have)Tj
2.0636 0 Td
(been)Tj
2.1203 0 Td
(used)Tj
2.058 0 Td
(to)Tj
-36.7821 -1.3039 Td
(improve)Tj
3.5773 0 Td
(adherence)Tj
4.3256 0 Td
(to)Tj
1.0261 0 Td
(ART)Tj
2.1373 0 Td
(and)Tj
1.7292 0 Td
(retention)Tj
3.9061 0 Td
(in)Tj
1.0375 0 Td
(care,)Tj
2.0976 0 Td
(but)Tj
1.5534 0 Td
(with)Tj
1.9955 0 Td
(variable)Tj
3.3562 0 Td
(impact)Tj
2.9821 0 Td
(on)Tj
1.2755 0 Td
(health)Tj
2.6759 0 Td
(outcomes)Tj
-33.6753 -1.2983 Td
([)Tj
0.83 0.64 0.02 0 k
(6)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.2585 0 Td
(7)Tj
0 g
(].)Tj
1.2643 0 Td
(While)Tj
2.6475 0 Td
(it)Tj
0.788 0 Td
(is)Tj
0.8448 0 Td
(likely)Tj
2.3584 0 Td
(that)Tj
1.7744 0 Td
(a)Tj
0.6577 0 Td
(multi-pronged)Tj
6.0888 0 Td
(approach)Tj
3.9514 0 Td
(is)Tj
0.8504 0 Td
(required,)Tj
3.8608 0 Td
(and)Tj
1.7291 0 Td
(no)Tj
1.2756 0 Td
(single)Tj
2.5341 0 Td
(intervention)Tj
-31.8838 -1.2983 Td
(will)Tj
1.661 0 Td
(work)Tj
2.2791 0 Td
(for)Tj
1.389 0 Td
(all)Tj
1.1451 0 Td
(young)Tj
2.7213 0 Td
(people)Tj
2.8573 0 Td
(short)Tj
2.2847 0 Td
(cycle)Tj
2.1883 0 Td
(therapy)Tj
3.2485 0 Td
(\(SCT\))Tj
2.6532 0 Td
(offers)Tj
2.4548 0 Td
(an)Tj
1.2019 0 Td
(innovative)Tj
4.4277 0 Td
(approach,)Tj
4.1782 0 Td
(with)Tj
1.9956 0 Td
(a)Tj
-36.6857 -1.3039 Td
(short)Tj
2.2847 0 Td
(weekly)Tj
2.948 0 Td
(`breather')Tj
4.0195 0 Td
(of)Tj
1.0148 0 Td
(a)Tj
0.6519 0 Td
(two-to-three)Tj
5.2611 0 Td
(days)Tj
1.9956 0 Td
(off)Tj
1.3039 0 Td
(treatment)Tj
4.1329 0 Td
(each)Tj
2.0296 0 Td
(week,)Tj
2.4718 0 Td
(aiming)Tj
3.0217 0 Td
(to)Tj
1.0261 0 Td
(preserve)Tj
-32.1616 -1.2982 Td
(adherence)Tj
4.3199 0 Td
(while)Tj
2.3698 0 Td
(improving)Tj
4.439 0 Td
(quality)Tj
2.9537 0 Td
(of)Tj
1.0148 0 Td
(life)Tj
1.4456 0 Td
(and)Tj
1.7292 0 Td
(maintaining)Tj
5.1193 0 Td
(virological)Tj
4.4107 0 Td
(suppression.)Tj
-26.6058 -1.2983 Td
(Adult)Tj
2.5058 0 Td
(studies)Tj
2.9877 0 Td
(showed)Tj
3.2485 0 Td
(promising)Tj
4.3483 0 Td
(short-term)Tj
4.5467 0 Td
(results)Tj
2.8063 0 Td
(of)Tj
1.0148 0 Td
(SCT)Tj
1.9729 0 Td
(strategies.)Tj
4.1499 0 Td
(In)Tj
1.1055 0 Td
(the)Tj
1.474 0 Td
(FOTO)Tj
2.8516 0 Td
(\(Five)Tj
-34.2082 -1.3039 Td
(On)Tj
1.5136 0 Td
(Two)Tj
2.024 0 Td
(Off\))Tj
1.8822 0 Td
(US)Tj
1.4286 0 Td
(trial,)Tj
2.0636 0 Td
(60)Tj
1.1736 0 Td
(virologically)Tj
5.108 0 Td
(suppressed)Tj
4.6147 0 Td
(adults)Tj
2.6136 0 Td
(on)Tj
1.2755 0 Td
(efavirenz)Tj
3.8438 0 Td
(\(EFV\))Tj
2.6929 0 Td
(and)Tj
1.7291 0 Td
(tenofovir)Tj
3.8835 0 Td
(dis-)Tj
-35.8467 -1.2983 Td
(oproxil)Tj
3.101 0 Td
(fumarate)Tj
3.8154 0 Td
(\(TDF\)-based)Tj
5.3802 0 Td
(ART)Tj
2.1373 0 Td
(were)Tj
2.1203 0 Td
(randomised)Tj
5.0059 0 Td
(to)Tj
1.0262 0 Td
(FOTO)Tj
2.8516 0 Td
(versus)Tj
2.7212 0 Td
(continuous)Tj
4.7339 0 Td
(therapy)Tj
-32.893 -1.2982 Td
(\(CT\).)Tj
2.398 0 Td
(All)Tj
1.3947 0 Td
(participants)Tj
4.9606 0 Td
(remained)Tj
4.0365 0 Td
(virologically)Tj
5.108 0 Td
(suppressed)Tj
4.6148 0 Td
(over)Tj
1.9729 0 Td
(48)Tj
1.1735 0 Td
(weeks)Tj
2.6079 0 Td
(follow-up)Tj
4.0932 0 Td
(and)Tj
-32.3601 -1.2983 Td
(expressed)Tj
4.0932 0 Td
(a)Tj
0.6519 0 Td
(strong)Tj
2.7723 0 Td
(preference)Tj
4.4333 0 Td
(for)Tj
1.389 0 Td
(SCT)Tj
1.9672 0 Td
([)Tj
0.83 0.64 0.02 0 k
(12)Tj
0 g
(].)Tj
2.0807 0 Td
(In)Tj
1.1055 0 Td
(a)Tj
0.6519 0 Td
(larger)Tj
2.5342 0 Td
(adult)Tj
2.2563 0 Td
(Ugandan)Tj
3.9118 0 Td
(trial)Tj
1.8369 0 Td
(\(57)Tj
1.5137 0 Td
(SCT;)Tj
2.194 0 Td
(56)Tj
1.1678 0 Td
(CT;)Tj
-34.5597 -1.3039 Td
(most)Tj
2.2053 0 Td
(on)Tj
1.2756 0 Td
(EFV\),)Tj
2.5738 0 Td
(there)Tj
2.2677 0 Td
(were)Tj
2.1203 0 Td
(11)Tj
1.1736 0 Td
(treatment)Tj
4.1328 0 Td
(failures)Tj
3.1408 0 Td
(in)Tj
1.0375 0 Td
(CT)Tj
1.491 0 Td
(versus)Tj
2.7212 0 Td
(6)Tj
0.6974 0 Td
(in)Tj
1.0318 0 Td
(SCT)Tj
1.9729 0 Td
([)Tj
0.83 0.64 0.02 0 k
(13)Tj
0 g
(].)Tj
2.0749 0 Td
(In)Tj
1.1112 0 Td
(a)Tj
0.652 0 Td
(single-arm)Tj
-31.6798 -1.2983 Td
(French)Tj
3.0387 0 Td
(trial)Tj
1.8368 0 Td
(in)Tj
1.0375 0 Td
(100)Tj
1.6497 0 Td
(predominantly)Tj
6.1795 0 Td
(white)Tj
2.4208 0 Td
(homosexual)Tj
5.04 0 Td
(adult)Tj
2.2563 0 Td
(males)Tj
2.5058 0 Td
(with)Tj
1.9956 0 Td
(virological)Tj
4.4107 0 Td
(suppression,)Tj
-32.3714 -1.2983 Td
(on)Tj
1.2755 0 Td
(boosted)Tj
3.3506 0 Td
(protease)Tj
3.5546 0 Td
(inhibitor)Tj
3.7814 0 Td
(\(PI\))Tj
1.7971 0 Td
(\(29%\))Tj
2.6136 0 Td
(or)Tj
1.0941 0 Td
(non-nucleotide)Tj
6.3666 0 Td
(reverse)Tj
3.0501 0 Td
(transcriptase)Tj
5.3291 0 Td
(inhibitor)Tj
-32.2127 -1.3039 Td
(based)Tj
2.4717 0 Td
(ART)Tj
2.1374 0 Td
(\(79%\),)Tj
2.8346 0 Td
(3)Tj
0.6916 0 Td
(days)Tj
2.0013 0 Td
(off)Tj
1.3039 0 Td
(treatment)Tj
4.1329 0 Td
(each)Tj
2.0296 0 Td
(week)Tj
2.245 0 Td
(was)Tj
1.7008 0 Td
(effective)Tj
3.5093 0 Td
(with)Tj
2.0012 0 Td
(96%)Tj
1.9276 0 Td
(remaining)Tj
4.3653 0 Td
(virologi-)Tj
-33.3522 -1.2982 Td
(cally)Tj
2.0239 0 Td
(suppressed)Tj
4.6091 0 Td
(at)Tj
0.9524 0 Td
(48)Tj
1.1735 0 Td
(weeks)Tj
2.6079 0 Td
([)Tj
0.83 0.64 0.02 0 k
(14)Tj
0 g
(].)Tj
-0.01 Tc
-10.1706 -1.2983 Td
(The)Tj
1.7688 0 Td
(BREATHER)Tj
5.193 0 Td
(trial)Tj
1.8085 0 Td
(was)Tj
1.6838 0 Td
(the)Tj
1.4513 0 Td
(first)Tj
1.7745 0 Td
(randomised)Tj
4.9492 0 Td
(controlled)Tj
4.2576 0 Td
(trial)Tj
1.8085 0 Td
(\(RCT\))Tj
2.7666 0 Td
(comparing)Tj
4.5184 0 Td
(the)Tj
1.4514 0 Td
(efficacy)Tj
-34.6278 -1.3039 Td
(and)Tj
1.7121 0 Td
(safety)Tj
2.4434 0 Td
(of)Tj
1.0035 0 Td
(SCT)Tj
1.9502 0 Td
(on)Tj
1.2642 0 Td
(EFV-based)Tj
4.5638 0 Td
(ART)Tj
2.1146 0 Td
(with)Tj
1.9729 0 Td
(two)Tj
1.6951 0 Td
(days)Tj
1.9729 0 Td
(a)Tj
0.6463 0 Td
(week)Tj
2.2224 0 Td
(off)Tj
1.2869 0 Td
(therapy)Tj
3.2031 0 Td
(versus)Tj
2.6873 0 Td
(CT)Tj
1.4796 0 Td
(in)Tj
1.0262 0 Td
(older)Tj
2.262 0 Td
(chil-)Tj
-35.5065 -1.2983 Td
(dren,)Tj
2.2847 0 Td
(adolescents)Tj
4.7111 0 Td
(and)Tj
1.7121 0 Td
(young)Tj
2.6929 0 Td
(adults.)Tj
2.795 0 Td
(The)Tj
1.7688 0 Td
(48)Tj
1.1565 0 Td
(week)Tj
2.2224 0 Td
(results)Tj
2.7665 0 Td
(showed)Tj
3.2202 0 Td
(that)Tj
1.7518 0 Td
(SCT)Tj
1.9502 0 Td
(was)Tj
1.6838 0 Td
(non-inferior)Tj
5.1477 0 Td
(to)Tj
-35.8637 -1.2983 Td
(CT)Tj
1.4796 0 Td
(for)Tj
1.372 0 Td
(maintenance)Tj
5.3234 0 Td
(of)Tj
1.0035 0 Td
(virological)Tj
4.3426 0 Td
(suppression)Tj
4.9153 0 Td
(with)Tj
1.9729 0 Td
(a)Tj
0.6463 0 Td
(similar)Tj
2.948 0 Td
(safety)Tj
2.4434 0 Td
(and)Tj
1.7121 0 Td
(resistance)Tj
4.0706 0 Td
(profile.)Tj
3.016 0 Td
(There)Tj
-35.2457 -1.2982 Td
(were)Tj
2.0976 0 Td
(no)Tj
1.2642 0 Td
(differences)Tj
4.5014 0 Td
(in)Tj
1.0205 0 Td
(low-level)Tj
3.7474 0 Td
(viraemia,)Tj
3.8664 0 Td
(adverse)Tj
3.1691 0 Td
(events,)Tj
2.914 0 Td
(advanced)Tj
3.9458 0 Td
(HIV)Tj
2.0069 0 Td
(stage)Tj
2.1713 0 Td
(events,)Tj
2.914 0 Td
(inflam-)Tj
-33.6186 -1.3039 Td
(matory)Tj
3.067 0 Td
(markers,)Tj
3.6737 0 Td
(HIV-1)Tj
2.8176 0 Td
(total)Tj
1.9786 0 Td
(DNA,)Tj
2.5738 0 Td
(or)Tj
1.0885 0 Td
(resistance)Tj
4.0705 0 Td
(mutations.)Tj
4.4504 0 Td
(At)Tj
1.1906 0 Td
(the)Tj
1.4513 0 Td
(end)Tj
1.7008 0 Td
(of)Tj
1.0034 0 Td
(the)Tj
1.4514 0 Td
(main)Tj
2.262 0 Td
(trial)Tj
1.8085 0 Td
(\(after)Tj
-34.5881 -1.2983 Td
(the)Tj
1.4513 0 Td
(last)Tj
1.5363 0 Td
(patient)Tj
2.9651 0 Td
(completed)Tj
4.354 0 Td
(48)Tj
1.1565 0 Td
(weeks)Tj
2.5795 0 Td
(follow-up\),)Tj
4.5921 0 Td
(90%)Tj
1.9105 0 Td
(of)Tj
1.0035 0 Td
(participants)Tj
4.8869 0 Td
(in)Tj
1.0205 0 Td
(the)Tj
1.4513 0 Td
(SCT)Tj
1.9559 0 Td
(group)Tj
2.5795 0 Td
(reported)Tj
-33.4429 -1.2983 Td
(that)Tj
1.7517 0 Td
(weekend)Tj
3.7077 0 Td
(breaks)Tj
2.778 0 Td
(made)Tj
2.3981 0 Td
(life)Tj
1.423 0 Td
(easier)Tj
2.4661 0 Td
(than)Tj
2.0012 0 Td
(daily)Tj
2.1203 0 Td
(ART,)Tj
2.3414 0 Td
(mainly)Tj
2.9537 0 Td
(due)Tj
1.6781 0 Td
(to)Tj
1.0148 0 Td
(freedom)Tj
3.5376 0 Td
(from)Tj
2.1827 0 Td
(needing)Tj
3.3845 0 Td
(to)Tj
-35.7389 -1.3039 Td
(carry)Tj
2.245 0 Td
(or)Tj
1.0828 0 Td
(take)Tj
1.8482 0 Td
(medications,)Tj
5.2554 0 Td
(thus)Tj
1.9105 0 Td
(enabling)Tj
3.6113 0 Td
(easier)Tj
2.4662 0 Td
(socialising)Tj
4.2973 0 Td
(with)Tj
1.9729 0 Td
(peers)Tj
2.2903 0 Td
(at)Tj
0.9411 0 Td
(weekends)Tj
4.0592 0 Td
([)Tj
0.83 0.64 0.02 0 k
(15)Tj
0 g
(].)Tj
2.0466 0 Td
(In)Tj
1.0942 0 Td
(a)Tj
-35.121 -1.2982 Td
(qualitative)Tj
4.3086 0 Td
(sub-study)Tj
4.0818 0 Td
(including)Tj
3.9855 0 Td
(43)Tj
1.1566 0 Td
(young)Tj
2.6929 0 Td
(people)Tj
2.8176 0 Td
(\(51%)Tj
2.2393 0 Td
(on)Tj
1.2643 0 Td
(SCT\),)Tj
2.5001 0 Td
(young)Tj
2.6929 0 Td
(people)Tj
2.8176 0 Td
(on)Tj
1.2586 0 Td
(SCT)Tj
1.9502 0 Td
(expressed)Tj
-33.766 -1.2983 Td
(a)Tj
0.6462 0 Td
(strong)Tj
2.7383 0 Td
(preference)Tj
4.371 0 Td
(for)Tj
1.3663 0 Td
(taking)Tj
2.6985 0 Td
(weekends-off)Tj
5.4652 0 Td
(treatment)Tj
4.0819 0 Td
(once)Tj
2.1033 0 Td
(they)Tj
1.8992 0 Td
(had)Tj
1.6894 0 Td
(adapted)Tj
3.3392 0 Td
(to)Tj
1.0148 0 Td
(a)Tj
0.652 0 Td
(new)Tj
1.8538 0 Td
(routine.)Tj
-33.9191 -1.3039 Td
(Many)Tj
2.5228 0 Td
(also)Tj
1.7461 0 Td
(reported)Tj
3.6113 0 Td
(improved)Tj
4.0592 0 Td
(adherence)Tj
4.269 0 Td
(to)Tj
1.0147 0 Td
(ART)Tj
2.1204 0 Td
(during)Tj
2.8913 0 Td
(the)Tj
1.4513 0 Td
(week)Tj
2.2223 0 Td
([)Tj
0.83 0.64 0.02 0 k
(16)Tj
0 g
(].)Tj
2.0466 0 Td
(A)Tj
0.9015 0 Td
(cost)Tj
1.7858 0 Td
(effectiveness)Tj
-30.6423 -1.2983 Td
(analysis)Tj
3.2768 0 Td
(showed)Tj
3.2144 0 Td
(significant)Tj
4.3257 0 Td
(total)Tj
1.9729 0 Td
(cost)Tj
1.7858 0 Td
(savings)Tj
3.0671 0 Td
(and)Tj
1.7121 0 Td
(non-significant)Tj
6.2532 0 Td
(total)Tj
1.9729 0 Td
(health)Tj
2.6419 0 Td
(benefits)Tj
3.2938 0 Td
(with)Tj
1.9729 0 Td
(SCT)Tj
-35.4895 -1.2983 Td
([)Tj
0.83 0.64 0.02 0 k
(17)Tj
0 g
(].)Tj
2.0466 0 Td
(In)Tj
1.0941 0 Td
(spite)Tj
2.058 0 Td
(of)Tj
1.0034 0 Td
(the)Tj
1.4513 0 Td
(success)Tj
3.0614 0 Td
(of)Tj
1.0035 0 Td
(this)Tj
1.6498 0 Td
(strategy,)Tj
3.4979 0 Td
(there)Tj
2.2337 0 Td
(were)Tj
2.0976 0 Td
(questions)Tj
3.9685 0 Td
(over)Tj
1.9502 0 Td
(longer-term)Tj
4.9833 0 Td
(efficacy)Tj
3.1691 0 Td
(on)Tj
-35.2684 -1.3039 Td
(SCT.)Tj
2.1713 0 Td
(Here)Tj
2.1826 0 Td
(we)Tj
1.3153 0 Td
(report)Tj
2.6702 0 Td
(the)Tj
1.4514 0 Td
(extended)Tj
3.8097 0 Td
(follow-up)Tj
4.0422 0 Td
(of)Tj
1.0034 0 Td
(the)Tj
1.4514 0 Td
(BREATHER)Tj
5.1987 0 Td
(trial)Tj
1.8028 0 Td
(for)Tj
1.372 0 Td
(an)Tj
1.1905 0 Td
(additional)Tj
4.2179 0 Td
(96)Tj
-33.8794 -1.2982 Td
(weeks,)Tj
2.7949 0 Td
(with)Tj
1.9729 0 Td
(original)Tj
3.2825 0 Td
(randomisation)Tj
6.0321 0 Td
(maintained)Tj
4.7281 0 Td
(to)Tj
1.0148 0 Td
(evaluate)Tj
3.4129 0 Td
(the)Tj
1.4514 0 Td
(durability)Tj
4.0591 0 Td
(of)Tj
1.0035 0 Td
(the)Tj
1.4513 0 Td
(SCT)Tj
1.9559 0 Td
(approach.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 183.0047 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Materials)Tj
4.5071 0 Td
(and)Tj
1.989 0 Td
(methods)Tj
/F13 1 Tf
-6.4961 -1.5023 Td
(Study)Tj
2.6173 0 Td
(design)Tj
2.915 0 Td
(and)Tj
1.7905 0 Td
(participants)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 148.0251 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(BREATHER)Tj
5.244 0 Td
([BREaks)Tj
3.6227 0 Td
(in)Tj
1.0374 0 Td
(Adolescent)Tj
4.6602 0 Td
(and)Tj
1.7291 0 Td
(child)Tj
2.2167 0 Td
(THerapy)Tj
3.7984 0 Td
(using)Tj
2.3867 0 Td
(Efavirenz)Tj
3.9912 0 Td
(and)Tj
1.7291 0 Td
(two)Tj
1.7121 0 Td
(nRtis])Tj
-32.1276 -1.3039 Td
(\(PENTA)Tj
3.719 0 Td
(16\),)Tj
1.7348 0 Td
(was)Tj
1.7008 0 Td
(a)Tj
0.6519 0 Td
(randomised,)Tj
5.2327 0 Td
(parallel-group,)Tj
6.1058 0 Td
(open-label,)Tj
4.6488 0 Td
(non-inferiority)Tj
6.2362 0 Td
(trial)Tj
1.8368 0 Td
(which)Tj
2.6532 0 Td
(has)Tj
-34.52 -1.2982 Td
(been)Tj
2.1203 0 Td
(previously)Tj
4.3539 0 Td
(described)Tj
4.0479 0 Td
([)Tj
0.83 0.64 0.02 0 k
(15)Tj
0 g
(].)Tj
2.0806 0 Td
(Briefly,)Tj
3.0727 0 Td
(eligible)Tj
3.0671 0 Td
(participants)Tj
4.9606 0 Td
(were)Tj
2.1203 0 Td
(aged)Tj
2.0693 0 Td
(824)Tj
2.1656 0 Td
(years,)Tj
2.4888 0 Td
(with)Tj
1.9956 0 Td
(a)Tj
0.6577 0 Td
(CD4)Tj
-35.2004 -1.2983 Td
(cell)Tj
1.5533 0 Td
(count)Tj
2.5228 0 Td
(of)Tj
/F12 1 Tf
0 Tc
1.0092 0 Td
()Tj
/F7 1 Tf
-0.004 Tc
(350)Tj
2.4151 0 Td
(cells/)Tj
/F14 1 Tf
[()]TJ
/F7 1 Tf
(L)Tj
3.2938 0 Td
(and)Tj
1.7291 0 Td
(a)Tj
0.6463 0 Td
(suppressed)Tj
4.6091 0 Td
(viral)Tj
1.9899 0 Td
(load)Tj
1.9333 0 Td
(of)Tj
/F15 1 Tf
0 Tc
1.0091 0 Td
(<)Tj
/F7 1 Tf
-0.004 Tc
(50)Tj
1.9389 0 Td
(copies/mL)Tj
4.405 0 Td
(for)Tj
1.3833 0 Td
(at)Tj
0.9467 0 Td
(least)Tj
1.9786 0 Td
(12)Tj
1.1679 0 Td
(months)Tj
-34.5314 -1.3039 Td
(on)Tj
1.2755 0 Td
(first-line)Tj
3.6397 0 Td
(EFV-based)Tj
4.6148 0 Td
(ART)Tj
2.1373 0 Td
(with)Tj
1.9956 0 Td
(two)Tj
1.7121 0 Td
(or)Tj
1.0998 0 Td
(three)Tj
2.262 0 Td
(nucleoside)Tj
4.4788 0 Td
(or)Tj
1.0941 0 Td
(nucleotide)Tj
4.4164 0 Td
(reverse)Tj
3.05 0 Td
(transcriptase)Tj
-31.7761 -1.2983 Td
(inhibitors)Tj
4.1385 0 Td
(\(NRTIs\).)Tj
3.7984 0 Td
(Exclusion)Tj
4.1329 0 Td
(criteria)Tj
3.0784 0 Td
(included)Tj
3.7134 0 Td
(pregnancy,)Tj
4.6317 0 Td
(concomitant)Tj
5.2951 0 Td
(medications)Tj
5.0967 0 Td
(for)Tj
1.389 0 Td
(acute)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 257.6692 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Weekends-)Tj
4.9819 0 Td
(off)Tj
1.3181 0 Td
(efaviren)Tj
3.4866 0 Td
(z-based)Tj
3.7205 0 Td
(antiretrov)Tj
4.0891 0 Td
(iral)Tj
1.5236 0 Td
(therapy:)Tj
3.7701 0 Td
(BREATHER)Tj
5.5985 0 Td
(extended)Tj
4.2661 0 Td
(follow-up)Tj
4.1387 0 Td
(results)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01962)Tj
4.089 0 Td
(39)Tj
0 g
2.0906 0 Td
(April)Tj
2.1827 0 Td
(23,)Tj
1.5874 0 Td
(2018)Tj
35.1357 0 Td
(3)Tj
0.7654 0 Td
(/)Tj
ET
endstream
endobj
59 0 obj
<>stream
endstream
endobj
60 0 obj
<>stream
endstream
endobj
61 0 obj
<>stream
endstream
endobj
62 0 obj
<>stream
endstream
endobj
63 0 obj
<>stream
endstream
endobj
64 0 obj
<>stream
endstream
endobj
65 0 obj
<>stream
endstream
endobj
66 0 obj
<>stream
endstream
endobj
67 0 obj
<>stream
endstream
endobj
68 0 obj
<>stream
endstream
endobj
69 0 obj
<>stream
endstream
endobj
70 0 obj
<>stream
endstream
endobj
71 0 obj
<>stream
endstream
endobj
72 0 obj
<>stream
endstream
endobj
73 0 obj
<>stream
endstream
endobj
74 0 obj
<>stream
endstream
endobj
75 0 obj
<>stream
BT
66.402 0 Td
(17)Tj
ET
Q
endstream
endobj
76 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 13 0 R/Annots 78 0 R/Contents 79 0 R/TrimBox[0 0 612 792]>>
endobj
77 0 obj
<>
endobj
80 0 obj
<>
endobj
81 0 obj
<>stream
%!PS-AdobeFont-1.0
11 dict begin
/FontName /PI_chars_3 def
/FontType 1 def
/FontBBox {-11 -345 1373 718} readonly def
/FontMatrix [0.001 0 0 0.001 0 0] readonly def
/PaintType 0 def
/FontInfo 8 dict dup begin
/FullName (PI_chars_3) readonly def
/BaseFontName (PI_chars_3) def
end def
/Encoding 256 array
0 1 255 {1 index exch /.notdef put} for
dup 33 /exclam put
dup 34 /quotedbl put
dup 35 /numbersign put
dup 36 /dollar put
dup 37 /percent put
dup 38 /ampersand put
dup 39 /quoteright put
dup 40 /parenleft put
dup 41 /parenright put
dup 42 /asterisk put
dup 43 /plus put
dup 44 /comma put
dup 45 /hyphen put
dup 46 /period put
dup 47 /slash put
dup 49 /one put
dup 50 /two put
dup 51 /three put
dup 52 /four put
dup 53 /five put
dup 54 /six put
dup 55 /seven put
dup 56 /eight put
dup 58 /colon put
dup 60 /less put
dup 61 /equal put
dup 62 /greater put
dup 63 /question put
dup 64 /at put
dup 65 /A put
dup 66 /B put
dup 67 /C put
dup 68 /D put
dup 69 /E put
dup 70 /F put
dup 71 /G put
dup 72 /H put
dup 73 /I put
dup 74 /J put
dup 75 /K put
dup 76 /L put
dup 77 /M put
dup 78 /N put
dup 79 /O put
dup 80 /P put
dup 81 /Q put
dup 82 /R put
dup 83 /S put
dup 84 /T put
dup 85 /U put
dup 86 /V put
dup 87 /W put
dup 88 /X put
dup 89 /Y put
dup 90 /Z put
dup 91 /bracketleft put
dup 92 /backslash put
dup 93 /bracketright put
dup 94 /asciicircum put
dup 97 /a put
dup 98 /b put
dup 99 /c put
dup 100 /d put
dup 101 /e put
dup 102 /f put
dup 103 /g put
dup 104 /h put
dup 105 /i put
dup 106 /j put
dup 107 /k put
dup 108 /l put
dup 109 /m put
dup 110 /n put
dup 111 /o put
dup 112 /p put
dup 113 /q put
dup 114 /r put
dup 115 /s put
dup 116 /t put
dup 117 /u put
dup 118 /v put
dup 119 /w put
dup 120 /x put
dup 121 /y put
dup 122 /z put
dup 123 /braceleft put
dup 124 /bar put
dup 125 /braceright put
dup 126 /asciitilde put
readonly def
currentdict end
currentfile eexec
M#1H5 J6o\&rtS(#v\0\V7Fe༙OYx5-cY9^%Y6
(efIOldN"wȰ;)UƽoFg/rvV$JS8_oc@
o9-eGJp}[Do]mN=4*{ܯq=eU^t6¤/{zM4aܪ
Q:д'B-r^ܦ6y?rRnu S\U{Oλrs(Βƚ
#d29%s'ƈT1F8&\0Xd&&Zug'VPd]:>u=Q,?#(CV4'..|ӱ5 h
sȀg)fɘ`UXK^>] q\l#5pE"JO}rquáQBr/E7
QW5\GSlu{7ZH(PSf/O;̟w{ɴ}-K hA8!b!U>`#u?Vlnǝ19V+mg'QmA}S Y$í8n uJ ڒx3>[x0Z]
ͩw4M&1+pkC,sr"%q&OjbH{:5$65*S`cr;%s4Oӆe>T+6~pBOD!$c]"~r#nh6$38i˞[~Z}}rHmte9(1½=j{<\ ;? RA?c{Rf1'VԞ_-Lwo]`.l|zjf"![G1BYro˓9[-+z g!}RN+pX!M~HcFh@g%J6B)6!Lq>TX\ݪGF
PiQݓX~Fs;Ölo4/(C?+,ɖxۼ:xU^)
fd,`*>-:}=q$:\Xzcw1Nf(
ZkEeJXfэi@zXc\{a5qKg\5ݩv\Qe%1>OY̗$Y#P[)."^+{"bP]Bt&zeN6
іijDE% 0;̅
~~lfB>u'i4znym%tfԟ^נBTDS6-ghiWk/(r!!˶fc>趕%U